Posted by Michael Wonder on 07 Mar 2026
US FDA approves Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis
6 March 2026 - Significantly more patients treated with once daily, oral Sotyktu achieved an ACR20 response compared with placebo at week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials.
Bristol Myers Squibb today announced that the US FDA has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
